Funds Holding Medicines

 
Stock Quotes for Medicines top ^
  • Industry: Medical Distribution
  • Sector: Healthcare
  • Stock Type: Distressed
Sign-up for chme investment picks
  • Industry: Drug Manufacturers - Specialty & Generic
  • Sector: Healthcare
  • Stock Style: Small Growth
  • Stock Type: Speculative Growth
Sign-up for mdco investment picks

 
News Articles for Medicines top ^
2014/9/16
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G021881-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/9/16/11G021881/87a481fe7b41ab6b_org-638840709.jpg ST.
Sign-up for All Children's Hospital Johns Hopkins Medicine Continues Fight Against Childhood Obesity With Grant From Kohl's Department Stores investment picks
"PIM" Designation For DCVax-L Is First Step In 2-Step Process for Early Access Approval BETHESDA, Md.
Sign-up for NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) investment picks
NORTH HOLLYWOOD, Calif., Sept.
Sign-up for IPC Continues Investment in Post-Acute Market With Acquisition of Clyo Internal Medicine in Ohio investment picks
The Medicines Company (NASDAQ:MDCO) has scheduled a webcast and conference call of its upcoming Infectious Disease Care Investor & Analyst Day on Wednesday, September 24, 2014, from 9:00 am to 12:00 pm Eastern Time.
Sign-up for The Medicines Company to Webcast Infectious Disease Care Investor & Analyst Day on September 24 investment picks
Presentations include first Phase 2 results evaluating investigational compound Veliparib in patients with non-small cell lung cancer NORTH CHICAGO, Ill.
Sign-up for AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting investment picks
Ross University School of Veterinary Medicine (RUSVM) has appointed Juan Samper, DVM, Ph.D. to the position of associate dean for clinical affairs.
Sign-up for Ross University School of Veterinary Medicine Appoints Dr. Juan Samper to Lead Clinical Training Program investment picks
DUBLIN, Ohio and CAMBRIDGE, Mass.
Sign-up for Cardinal Health Specialty Solutions, KEW Group Bring Power of Personalized Medicine to Community Oncologists investment picks
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the European Medicines Agency (EMA) has validated for review the Marketing Authorization Application (MAA) for nivolumab in non-small cell lung cancer (NSCLC) – the first completed regulatory submission for a PD-1 immune checkpoint inhibitor in this tumor type.
Sign-up for European Medicines Agency Validates the Marketing Authorization Application for Nivolumab in Non-Small Cell Lung Cancer investment picks
Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today reviewed recent progress and announced upcoming milestones in its efforts to develop multiple combinations of medicines that treat the underlying cause of cystic fibrosis (CF) for the majority of people with the disease.
Sign-up for Vertex Reviews Recent Progress and Announces Upcoming Milestones in the Development of Multiple Combinations of Medicines that Target the Underlying Cause of Cystic Fibrosis investment picks
The Medicines Company (NASDAQ:MDCO) has scheduled its quarterly conference call for Wednesday, October 22 at 8:30 a.m. Eastern Time to discuss third quarter financial results, guidance and operational developments.
Sign-up for The Medicines Company to Announce Third Quarter 2014 Financial Results on Wednesday, October 22, 2014 investment picks
The Medicines Company (NASDAQ:MDCO) today announced that data from its infectious disease portfolio will be presented at ID Week 2014, October 8-12 in Philadelphia, Pennsylvania.
Sign-up for The Medicines Company Infectious Disease Portfolio Data to Be Presented at ID Week 2014 investment picks
MORRIS PLAINS, N.J., Oct.
Sign-up for Immunomedics Announces Presentations at the 2014 European Association of Nuclear Medicine Congress investment picks
WOODCLIFF LAKE, N.J. and SAN DIEGO , Oct.
Sign-up for Eisai and Arena Pharmaceuticals Announce Publication of Pooled Phase 3 Clinical Trial Analysis of BELVIQ® (lorcaserin HCl) CIV in Postgraduate Medicine investment picks
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has concluded its review of Iclusig ® (ponatinib) under the Article 20 referral procedure and has recommended that Iclusig continue to be used in Europe in accordance with its already approved indications.
Sign-up for ARIAD Announces Recommendation for Iclusig by the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency investment picks
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that financial results for the company’s third quarter ended September 30, 2014, will be released on Wednesday, November 5, 2014.
Sign-up for Foundation Medicine Announces Timing for Third Quarter 2014 Financial Results and Conference Call investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Funds Holding Medicines
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Funds Holding Medical Properties Trust, Inc.  |  Next: Funds Holding Medidata Solutions, Inc.